Paul Grena, DO
Cardiovascular Disease · Yardley, PANPI 1851365308
Payments from drug & device makers
Across 536 payments — averaging $2925.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$784K
- Novartis$502K
- Janssen Research & Development, LLC$183K
- Kiniksa Pharmaceuticals, Ltd.$37K
- Amarin Pharma, Inc.$18K
- Pfizer$11K
- plus $34K from 26 others
Across 6 payments — averaging $5207.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$31K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 96 | $784,091 |
| Novartis | 61 | $501,797 |
| Janssen Research & Development, LLC | 53 | $183,032 |
| Kiniksa Pharmaceuticals, Ltd. | 20 | $36,555 |
| Amarin Pharma, Inc. | 24 | $17,663 |
| Pfizer | 42 | $11,292 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Merck | 50 | $6,520 |
| AstraZeneca | 18 | $6,356 |
| Boehringer Ingelheim | 6 | $5,534 |
| Boehringer Ingelheim International GmbH | 19 | $3,603 |
| Bayer | 7 | $2,352 |
| Amgen | 49 | $882 |
| Johnson & Johnson | 21 | $379 |
| Novo Nordisk | 12 | $240 |
| Esperion Therapeutics, Inc. | 13 | $226 |
| Lexicon Pharmaceuticals, Inc. | 6 | $135 |
| E.r. Squibb & Sons, L.L.C. | 8 | $128 |
| Cleerly, Inc. | 1 | $127 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $101 |
| Lilly USA, LLC | 2 | $93 |
| Boston Scientific | 4 | $86 |
| Scpharmaceuticals Inc. | 3 | $72 |
| Impulse Dynamics (USA) Inc. | 2 | $57 |
| Edwards Lifesciences | 2 | $45 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Endotronix, Inc. | 1 | $15 |
How this compares
$1,568,248 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Yardley
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
- Peter KoweyWynnewood$1.6M
- Chinmay PatelLancaster$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.